The way to prevent postoperative detachment ciliochoroidal

 

(57) Abstract:

Usage: in ophthalmology at the prevention of postoperative ciliochoroidal detachment. The inventive before and after surgery podkonyunktivalno enter contrical 300 Acre, and during the operation it is introduced in the form of instillation.

The invention relates to medicine, namely to ophthalmology.

Known methods of prevention ciliochoroidal detachment, providing for the introduction under the conjunctiva of the operated eye caffeine, dicynone with oral assignment verospiron and digoxin /1/, podklyuchenie injection of glycerol /3/, emoxipin /4/.

Closest to the invention method, based on the use of steroids, Mydriatics, angioprotectors /2/.

However, when applying the above method, the rate of postoperative detachment is quite high.

Our research found that ciliochoroidal detachment is accompanied by increased activity of lysosomal enzymes /cathepsin D and B) in suprachoroidal fluid and in the serum of patients going on intraocular surgery, compared with the control group patients. Therefore, prevention silizium the cell membrane and prevents the release of enzymes from damaged cells during surgical trauma and prevents the development of retinal vascular sheath.

The aim of the invention is to reduce postoperative ciliochoroidal detachment.

This goal is achieved by applying podklyucheniya injection kontrikala /300 ATaE/ on the operating table before the surgery, instillaciei working solution kontrikala in breeding 1000 ATpE/ ml of saline solution during surgery and after surgery introduction under the conjunctiva 300 ATpE kontrikala through day N 3-4.

Example. The patient-and MT 1928 R. was admitted to the hospital 11.3.93, diagnosed with open-angle 3-4 glaucoma of the left eye, open 1 and glaucoma of the right eye I. B. N 1779/312. 12.3.93 were deep sclerectomy by S. N. Fedorov, on the operating table before the operation under the conjunctiva introduced 300 ATpE /0.3 ml working solution kontrikala in breeding 1000 ATpE/ml saline/ kontrikala. During the operation after iridectomy has istrirovali working solution kontrikala. Then every other day during the week subkonyunktivalno introduced 300 ATpE /0.3 ml/ kontrikala in the amount of 3 injections. The postoperative period was uneventful, detachment of the choroid has not developed.

Under the proposed method conducted prevention 21 patient. All pain is observed.

Thus, the proposed method is compared with the prototype of the most effective.

The way to prevent postoperative ciliochoroidal detachment involving the introduction of anti-inflammatory drugs under the conjunctiva, characterized in that as anti-inflammatory agents use contrical that is administered in the form of a solution before surgery in the amount of 300 Acre during surgery by instillation and after a specific intervention on the 300 Acre during the week through the day.

 

Same patents:

Drug for analgesia // 2077326
The invention relates to the field of pharmacology, drug substances

The invention relates to new biologically active compounds derived boron-containing peptides and pharmaceutical composition having inhibitory activity to trypsinogen serine proteases, which can find application in biology and medicine

The invention relates to new amino acid derivatives and their pharmaceutically acceptable salts, specifically to new amino acid derivatives and their pharmaceutically acceptable salts, which have an inhibiting activity against renin, to methods for their preparation, to pharmaceutical compositions containing them and to a method for the treatment of hypertension and heart failure in humans or animals

The invention relates to the field of polymer chemistry, medicine and biochemistry, and in particular to method of obtaining insulinaemia polymer hydrogels

The invention relates to medicine, namely to treatment antiproteinase drugs, and can be used for correction of conditions associated with increased proteolytic activity in the tissues, blood and other biological fluids

The invention relates to biotechnology, namely to methods for enzyme inhibitors, in particular inhibitors of cysteine proteases from plant material inhibitor bromeline

The invention relates to biochemistry

The invention relates to medical engineering, in particular to instruments for ophthalmic operations
The invention relates to ophthalmology, namely, to methods of surgical correction of aniridia
The invention relates to medicine, namely to ophthalmology, and is intended for operative treatment of patients with myopia

The invention relates to the field of ophthalmology for the treatment of vascular thinning, uneven Belm

The invention relates to medicine, namely to methods of disease prevention and treatment of eye
The invention relates to the field of medicine and more specifically to ophthalmology
The invention relates to ophthalmology, namely the treatment of vascular disease of the eye
The invention relates to the field of medicine and more specifically to ophthalmology

The invention relates to medicine, specifically to ophthalmology, and can be used for the surgical treatment of complicated retinal detachment
The invention relates to ophthalmic surgery, and in particular to methods of removal of an eyeball in intraocular tumors

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing hypotensive means by means of instillations. Eye drops of emoxipin are instilled 20-30 min later twice a day during 4-8 weeks. The treatment course is repeated in 2-3 months.

EFFECT: improved vision function; normalized hemodynamic values.

1 tbl

Up!